The global demand for Cancer Supportive Care Drugs Market is presumed to reach the valuation of nearly USD XX MN by 2028 from USD XX MN in 2021 with a CAGR of XX% during the period of 2022-2028.
Cancer care supportive drugs are those drugs that are used to reduce the injurious side effects of cancer treatment by protecting specific organs or cells. These drugs are not used for cancer treatment. Supportive drugs are sometimes also called as protective drugs. The major drug classes involved in cancer supportive care include ESAs for the treatment of Anemia (CIA), G-CSFs for neutropenia (CIN), bisphosphonates for cancer-induced bone diseases, antiemetics for nausea and vomiting (CINV), and NSAIDs for treating cancer pain. The side effects of cancer supportive drugs will depend primarily on: drug type, the dose given, and the overall health of the patients.
Market Dynamics
The increasing prevalence of cancer globally and many side effects associated with cancer treatment are the major factors driving the cancer supportive care drug market over the forecast time frame. In addition to that, increasing uptake of biosimilars and the availability of effective treatment methods are other factors that add fuel to the growth of the cancer supportive care drugs market. Also, rising expenditure on healthcare and beneficial healthcare reforms worldwide are positively impacting market growth. Moreover, the technological advancements in targeted therapy drugs, which have lesser side effects than traditional cancer therapy drugs, is anticipated to give rise to more demand in the coming years.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of cancer supportive care drugs.
Market Segmentation
The entire cancer supportive care drugs market has been sub-categorized into therapeutic class. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Therapeutic Class
- G-CSFs (Granulocyte-colony Stimulating Factors)
- ESAs (Erythropoiesis Stimulating Agents)
- Anti-Emetics
- Bisphosphonates
- Opioids
- (Non Steroidal Anti-Inflammatory Drugs) NSAIDs
Regional Analysis
This section covers regional segmentation which accentuates on current and future demand for cancer supportive care drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Cancer Supportive Care Drugs Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the cancer supportive care drugs market include Amgen Inc., Merck & Co., Johnson & Johnson SeRvices, Inc., Heron Theovartis, Novartis AG, Tesaro, Inc., F. Hoffmann-La Roche AG, Helsinn Healthcare SA, Teva Pharmaceuticals, 3SBio, BioSidus. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.